Status:

COMPLETED

A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA

Lead Sponsor:

AstraZeneca

Collaborating Sponsors:

Contract Research Organization: USA

PAREXEL Early Phase Clinical Unit Baltimore

Conditions:

Asymptomatic Hyperuricemia

Eligibility:

All Genders

18-99 years

Phase:

PHASE2

Brief Summary

This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinu...

Detailed Description

This is a randomized, placebo controlled, double-blind, 2-way crossover study to assess the effect of intensive UA lowering therapy with verinurad (RDEA3170), febuxostat, and dapagliflozin on urinary ...

Eligibility Criteria

Inclusion

  • 18 to 65 years old
  • Asymptomatic hyperuricemia (sUA \> 6.0 mg/dL)
  • Body mass index between 18 and 35 kg/m2 inclusive and weight at least 50 kg and no more than 150 kg
  • Females must be non-pregnant, as well as post-menopausal or willing to use an acceptable method of contraception during the study.

Exclusion

  • History of any clinically significant disease or disorder putting the patient at risk during the study, or influencing study results or ability to participate in the study
  • eGFR\* \< 45 mL/minute/1.73 m2 at Screening.
  • Type 2 diabetes mellitus with HbA1c \>8%.
  • History of diabetic ketoacidosis, hyperosmolar non-ketotic coma, gout, or alcohol or drug abuse.
  • Ongoing treatment with an SGLT2-inhibitor, a URAT1-inhibitor, and/or a xanthine oxidase inhibitor.
  • Positive test for hepatitis B, hepatitis C or HIV.
  • Use of any medications in the 2 weeks preceding first administration of study drug.

Key Trial Info

Start Date :

October 25 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 19 2018

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT03316131

Start Date

October 25 2017

End Date

July 19 2018

Last Update

August 28 2019

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Research Site

Glendale, California, United States, 91206

2

Research Site

Baltimore, Maryland, United States, 21225